CytomX Therapeutics CTMX Retained Earnings
Retained Earnings at other companies
Other financials
Where this comes from
Reported directly by CytomX Therapeutics in its filing.
Tagged under the XBRL concept us-gaap:RetainedEarningsAccumulatedDeficit.
The official record: CytomX Therapeutics’s 10-Q, filed May 7, 2026, on SEC EDGAR. View the filing →
Ask your AI about CytomX Therapeutics's retained earnings.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is CytomX Therapeutics's retained earnings?
- CytomX Therapeutics (CTMX) reported retained earnings of -$730.2M in Q1 2026.
- How has CytomX Therapeutics's retained earnings changed year-over-year?
- CytomX Therapeutics's retained earnings decreased by 9.3% year-over-year, from -$668.05M to -$730.2M.
- What is the long-term trend for CytomX Therapeutics's retained earnings?
- Over 5 years (2020 to 2025), CytomX Therapeutics's retained earnings has grown at a 7.0% compound annual growth rate (CAGR), from -$507.69M to -$711.95M.
- What does retained earnings mean?
- Cumulative net income earned since inception minus all dividends paid — the total profits reinvested in the business over its lifetime.